Role of Pten in leukemia stem cells
作者： Dongguang Li , Yaoyu Chen , Shaoguang Li , Cong Peng
DOI: 10.18632/ONCOTARGET.100603
关键词:
摘要: Received: May 5, 2010 , Accepted: 18, Published: June 7, // Chronic myeloid leukemia (CML) is initiated from the BCR-ABL-expressing stem cells (LSCs). These LSCs are highly resistant to BCR-ABL kinase inhibitors, imatinib, dasantinib and nilotinib, methods for eradication of still not available. It critical identify genes that play roles in survival proliferation LSCs. We recently discovered tumor suppressor gene Pten downregulated CML mice. By genetic deletion or overexpression Pten, we confirmed functions as a CML, consistent with role acute (AML) progenitor T-ALL progenitors. Functional enhancement pathway provides therapeutic strategy targeting
sci-hub.st 参考文章(43)
Y. Hu, S. Swerdlow, T. M. Duffy, R. Weinmann, F. Y. Lee, S. Li, Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 16870- 16875 ,(2006) , 10.1073/PNAS.0606509103
Chen Zhao, Jordan Blum, Alan Chen, Hyog Young Kwon, Seung Hye Jung, J. Michael Cook, Anand Lagoo, Tannishtha Reya, Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo Cancer Cell. ,vol. 12, pp. 528- 541 ,(2007) , 10.1016/J.CCR.2007.11.003
Jorge Cortes, Susan O'Brien, Hagop Kantarjian, Discontinuation of imatinib therapy after achieving a molecular response. Blood. ,vol. 104, pp. 2204- 2205 ,(2004) , 10.1182/BLOOD-2004-04-1335
Mercedes E Gorre, Mansoor Mohammed, Katharine Ellwood, Nicholas Hsu, Ron Paquette, P Nagesh Rao, Charles L Sawyers, Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification Science. ,vol. 293, pp. 876- 880 ,(2001) , 10.1126/SCIENCE.1062538
Bangyan Stiles, Matthias Groszer, Shunyou Wang, Jing Jiao, Hong Wu, PTENless means more. Developmental Biology. ,vol. 273, pp. 175- 184 ,(2004) , 10.1016/J.YDBIO.2004.06.008
Yaoyu Chen, Yiguo Hu, Haojian Zhang, Cong Peng, Shaoguang Li, Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia Nature Genetics. ,vol. 41, pp. 783- 792 ,(2009) , 10.1038/NG.389
Philippe Rousselot, Francoise Huguet, Delphine Rea, Laurence Legros, Jean Michel Cayuela, Odile Maarek, Odile Blanchet, Gerald Marit, Eliane Gluckman, Josy Reiffers, Martine Gardembas, François-Xavier Mahon, , Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood. ,vol. 109, pp. 58- 60 ,(2007) , 10.1182/BLOOD-2006-03-011239
Neil P. Shah, John M. Nicoll, Bhushan Nagar, Mercedes E. Gorre, Ronald L. Paquette, John Kuriyan, Charles L. Sawyers, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell. ,vol. 2, pp. 117- 125 ,(2002) , 10.1016/S1535-6108(02)00096-X
Ravi Bhatia, Melissa Holtz, Ning Niu, Rachel Gray, David S. Snyder, Charles L. Sawyers, Daniel A. Arber, Marilyn L. Slovak, Stephen J. Forman, Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. ,vol. 101, pp. 4701- 4707 ,(2003) , 10.1182/BLOOD-2002-09-2780
M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, M. F. Clarke, Prospective identification of tumorigenic breast cancer cells Proceedings of the National Academy of Sciences of the United States of America. ,vol. 100, pp. 3983- 3988 ,(2003) , 10.1073/PNAS.0530291100